Wall Street analyst estimates for Cogent Biosciences, Inc. (COGT): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST).
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $6.0M | $2.4M – $8.6M | $-2.22 | 8 |
| 2027E | $284M | $163M – $399M | $-1.09 | 8 |
| 2028E | $761M | $407M – $1.1B | $0.84 | 8 |
Figures in USD · consensus as of October 29, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 10 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 12 |
| Avg rating (−2 sell to +2 buy) | 0.83 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-06 | $-0.56 | ||
| 2026-08-10 | $-0.52 | $-0.55 | +6.3% |
| 2026-05-05 | $-0.53 | $-0.53 | +0.0% |
| 2026-02-17 | $-0.55 | $-0.51 | -7.8% |
| 2025-11-07 | $-0.50 | $-0.54 | +7.4% |
| 2025-08-05 | $-0.53 | $-0.55 | +3.6% |
| 2025-05-06 | $-0.52 | $-0.56 | +7.1% |
| 2025-02-25 | $-0.61 | $-0.59 | -3.4% |
Valuation Ratios
| Price / Book | 10.20 |
| EV / EBITDA | -15.06 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.4M | $8.4M | $9.7M | $22.5M | $7.9M | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | $43,709 | $25.7M | 0 | 0 | 0 | 0 | $4.6M |
| Gross Profit | $6.4M | $8.4M | $9.7M | $22.5M | -$17.9M | 0 | 0 | 0 | 0 | -$4.6M |
| Research & Development | $22.0M | $29.8M | $38.3M | $43.7M | $72.6M | $55.9M | $121.6M | $173.8M | $232.7M | $269.8M |
| Selling, General & Admin | $3.4M | $4.7M | $7.5M | $11.0M | $17.4M | $19.6M | $26.2M | $34.4M | $43.3M | $63.6M |
| Operating Expenses | $25.4M | $34.5M | $45.7M | $54.7M | $64.3M | $75.6M | $147.8M | $208.1M | $275.9M | $328.7M |
| Operating Income | -$19.1M | -$26.2M | -$36.0M | -$32.2M | -$82.2M | -$75.6M | -$147.8M | -$208.1M | -$275.9M | -$333.4M |
| EBITDA | -$18.2M | -$25.0M | -$34.7M | -$30.9M | -$34.6M | -$72.1M | -$130.4M | -$188.8M | -$251.5M | -$321.3M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | $4.0M | 0 | 0 | $3.1M |
| Pre-tax Income | -$18.1M | -$25.5M | -$34.5M | -$31.8M | -$74.8M | -$72.3M | -$140.2M | -$192.4M | -$255.9M | -$328.9M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$18.1M | -$25.5M | -$34.5M | -$30.3M | -$74.8M | -$72.3M | -$140.2M | -$192.4M | -$255.9M | -$328.9M |
| EPS | $-3.10 | $-3.45 | $-5.55 | $-3.97 | $-6.00 | $-1.85 | $-2.26 | $-2.42 | $-2.32 | $-2.04 |
| EPS (Diluted) | $-2.45 | $-3.45 | $-5.55 | $-3.97 | $-6.00 | $-1.85 | $-2.26 | $-2.42 | $-2.32 | $-2.04 |
| Shares Outstanding (Diluted) | 7.4 M | 7.4 M | 6.2 M | 7.6 M | 11.1 M | 38.7 M | 58.7 M | 79.7 M | 110.5 M | 161.0 M |
Price
| Price | $31.02 (closing price, October 30, 2026) |
| Market Cap | $5.4B |
| Exchange | NASDAQ |
| Country | US |
Related companies: INCY · IDYA · TNGX · NRIX · RCUS
Explore sector: Healthcare · Biotechnology
More sections of COGT: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks